Flupirtine-based pain therapy

Drug Profile

Flupirtine-based pain therapy

Alternative Names: CNSB001; CNSB015

Latest Information Update: 01 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CNSBio
  • Developer Relevare Pharmaceuticals
  • Class Aminopyridines; Muscle relaxants; Non-opioid analgesics; Opiate alkaloids; Small molecules
  • Mechanism of Action KCNQ potassium channel agonists; Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies; Neuropathic pain

Most Recent Events

  • 31 May 2010 Interim efficacy data from a phase IIa trial in HIV-related Neuropathic pain released by Relevare Pharmaceuticals
  • 28 May 2010 Relevare Pharmaceuticals completes a phase II trial in Neuropathic pain in Australia
  • 07 Oct 2008 Phase-I/II clinical trials in Neuropathic pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top